MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'European Journal of Cancer' source. Wed, 08 Feb 2012 08:41:32 +0100 http://www.medworm.com/index.php?rid=5638183&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009671%2Fabstract%3Frss%3Dyes Abstract: Introduction: In the phase III RECORD-1 trial (ClinicalTrials.gov: NCT00410124), patients with metastatic renal cell carcinoma (mRCC) who progressed on previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy were randomised 2:1 to everolimus 10mg once daily (n=277) or placebo (n=139). Median progression-free survival (PFS) was 4.9months with everolimus and 1.9months with placebo (hazard ratio [HR], 0.33; P (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638183 Tue, 03 Jan 2012 05:00:00 +0100 5638183 http://www.medworm.com/index.php?rid=5552138&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007945%2Fabstract%3Frss%3Dyes Conclusion: The existence of significant social disparities in ALL survival, which are not due to treatment accessibility, is of major clinical importance. Trends should be monitored and further research into potentially modifiable risk factors conducted. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552138 Sat, 31 Dec 2011 01:52:50 +0100 5552138 http://www.medworm.com/index.php?rid=5638193&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009944%2Fabstract%3Frss%3Dyes Please note that the title of this article was expanded incorrectly during editing but unfortunately this error was not picked up during proof correction. The correct title is as follows: (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638193 Thu, 29 Dec 2011 05:00:00 +0100 5638193 http://www.medworm.com/index.php?rid=5638184&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009683%2Fabstract%3Frss%3Dyes Abstract: Objective: We conducted a systematic review of the literature and performed a meta-analysis to determine the risk of developing skin rash and stomatitis among patients receiving temsirolimus.Methods: Databases from PubMed and Web of Science from January, 1998 until June, 2011 and abstracts presented at the American Society of Clinical Oncology annual meetings from 2004 through 2011 were searched to identify relevant studies. The incidence and relative risk (RR) of skin rash and stomatitis were calculated using random-effects or fixed-effects model depending on the heterogeneity of included studies.Results: A total of 779 patients from 10 clinical trials were included in this analysis. The overall incidence of all-grade rash was 45.8% (95% confidence interval (CI): 35.6–56.3%), ... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638184 Thu, 29 Dec 2011 05:00:00 +0100 5638184 http://www.medworm.com/index.php?rid=5638187&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009634%2Fabstract%3Frss%3Dyes Conclusions: The prophylactic use of G-CSF during induction of ALL is associated with improved long-term outcome and should be recommended especially in a setting of T-ALL and in ‘young adults’. Our analysis provides the first direct evidence coming from prospective trials for the impact of primary G-CSF prophylaxis on disease-free survival of oncological patients. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638187 Mon, 26 Dec 2011 05:00:00 +0100 5638187 http://www.medworm.com/index.php?rid=5552141&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009348%2Fabstract%3Frss%3Dyes This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This paper has been retracted at the request of the Editors of the European Journal of Cancer and the authors of the paper. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552141 Mon, 19 Dec 2011 05:00:00 +0100 5552141 http://www.medworm.com/index.php?rid=5552129&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009361%2Fabstract%3Frss%3Dyes Conclusions: This phase II study suggests that sunitinib monotherapy demonstrated marginal efficacy in metastatic BTC patients although toxicity should be concerned in Asian population. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552129 Mon, 19 Dec 2011 05:00:00 +0100 5552129 http://www.medworm.com/index.php?rid=5638192&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009063%2Fabstract%3Frss%3Dyes Conclusions: The dual PI3K-mTOR inhibitor NVP-BEZ235 was found to reduce cell proliferation and to induce apoptosis in 3-D cultured colon carcinoma cells, NVP-BEZ235 is a promising candidate for use in sequential treatment modalities together with cytotoxic drugs to reduce the cell mass of solid tumours. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638192 Fri, 09 Dec 2011 05:00:00 +0100 5638192 http://www.medworm.com/index.php?rid=5552133&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009038%2Fabstract%3Frss%3Dyes In this study the ELD-making process in HGG patients is described.Methods: Physicians and relatives of a cohort of 155 deceased HGG patients were identified to fill in a questionnaire regarding the end-of-life conditions (patients’ ELD preferences, patients’ competence) and ELD-making (forgoing treatment and the administration of drugs with a potential life-shortening effect) for their patient or relative. Data were analysed with descriptive statistics.Findings: Of 101 patients, physicians completed surveys including questions about ELDs (62% response rate). More than half of the patients relatively early became incompetent to make decisions due to delirium, cognitive deficits and/or decreasing consciousness. In 40% of patients the physician did not discuss ELD preferences with his/her... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552133 Wed, 07 Dec 2011 05:00:00 +0100 5552133 http://www.medworm.com/index.php?rid=5552125&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007374%2Fabstract%3Frss%3Dyes Abstract: We provide updated estimates of survival, incidence, complete prevalence, and proportion cured for patients with testicular/paratesticular and extragonadal germ cell cancers in Europe, grouped according to the new list of cancer types developed by RARECARE. We collected data, archived in European cancer registries, with vital status information available to 31st December 2003.We analysed 26,000 cases of testicular, paratesticular and extragonadal germ cell cancers diagnosed 1995–2002, estimating that about 15,600 new testicular/paratesticular and 630 new extragonadal cancer cases occurred per year in EU27, with annual incidence rates of 31.5/1,000,000 and 1.27/1,000,000, respectively. Slightly more than 436,000 persons were alive at the beginning of 2008 with a diagnosis of tes... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552125 Tue, 06 Dec 2011 05:00:00 +0100 5552125 http://www.medworm.com/index.php?rid=5638180&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911009014%2Fabstract%3Frss%3Dyes Abstract: Tetraploidy and aneuploidy can be caused by cell division errors and are frequently observed in many human carcinomas. We have recently reported delayed cytokinesis in primary human fibroblasts from BRCA2 mutation carriers, implying a function for the BRCA2 tumour suppressor in completion of cell division. Here, we address ploidy aberrations in breast tumours derived from BRCA2 germline mutation carriers. Ploidy aberrations were evaluated from flow cytometry histograms on selected breast tumour samples (n=236), previously screened for local BRCA mutations. The ploidy between BRCA2-mutated (n=71) and matched sporadic (n=165) cancers was compared. Differences in ploidy distribution were examined with respect to molecular tumour subtypes, previously defined by immunohistochemistry o... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638180 Fri, 02 Dec 2011 05:00:00 +0100 5638180 http://www.medworm.com/index.php?rid=5457100&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008331%2Fabstract%3Frss%3Dyes (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457100 Thu, 01 Dec 2011 01:54:54 +0100 5457100 http://www.medworm.com/index.php?rid=5494691&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008215%2Fabstract%3Frss%3Dyes Conclusion: While siltuximab plus M/P appeared well tolerated, improvement in outcomes was not demonstrated. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494691 Wed, 30 Nov 2011 05:00:00 +0100 5494691 http://www.medworm.com/index.php?rid=5638191&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008756%2Fabstract%3Frss%3Dyes Abstract: Pituitary adenomas are the common neoplasms that cause mass effect and/or endocrine dysfunction. Studies in the pathogenesis and functional regulation of pituitary adenomas are mainly focused on the following two topics: (a) the origin of pituitary adenomas and abnormal physical adjustment due to the activation of oncogenes and loss of function for tumour-suppressor genes; and (b) the mechanistic anomalies of the intracellular signal transduction. Among which, the Raf/MEK/ERK signalling has been considered to be one of the major and central pathways in disease aetiology. Raf/MEK/ERK signalling is evolutionarily conserved that controls cellular growth, differentiation and survival. Altered functionality of this signalling pathway has been found to be involved in the development of... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638191 Mon, 28 Nov 2011 05:00:00 +0100 5638191 http://www.medworm.com/index.php?rid=5638178&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008719%2Fabstract%3Frss%3Dyes Conclusion: Plitidepsin administered to children as a 3-h infusion every 2weeks is received with manageable toxicity for children with cancer, and the RD is 5mg/m2. Pharmacokinetic parameters in children and adolescents are comparable to adults. Future phase II studies of plitidepsin are warranted, and our results suggest that plitidepsin could be appropriately developed in combination with other antitumour where myelosuppression is dose-limiting. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638178 Mon, 28 Nov 2011 05:00:00 +0100 5638178 http://www.medworm.com/index.php?rid=5552142&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008641%2Fabstract%3Frss%3Dyes Please note that the order of authors is incorrect in the published version of this abstract. The first author is M. Patel as stated above, and not M. Webber. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552142 Mon, 28 Nov 2011 05:00:00 +0100 5552142 http://www.medworm.com/index.php?rid=5552131&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008227%2Fabstract%3Frss%3Dyes Abstract: Aim: To assess docetaxel–estramustine in patients with localised high-risk prostate cancer.Patients and methods: After staging pelvic lymph node dissection, patients with high-risk prostate cancer randomly received androgen deprivation therapy (ADT) (3years)+DE (4 cycles of docetaxel 70mg/m2/3weeks+estramustine 10mg/kg/dd1–5) or ADT alone. Local therapy was administered at 3months.Results: Four hundred and thirteen patients were accrued: T3–T4 (67%), Gleason score ⩾8 (42%), PSA >20ng/mL (59%), pN+ (29%). In the chemotherapy arm, 94% of patients received the planned four cycles of docetaxel. Local treatment consisted of radiotherapy in 358 patients (87%) (median dose 74Gy in both arms). ADT was given for 36months in both arms. A PSA response (PSA ⩽0.2ng/mL after 3months ... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552131 Mon, 28 Nov 2011 05:00:00 +0100 5552131 http://www.medworm.com/index.php?rid=5552127&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008744%2Fabstract%3Frss%3Dyes Conclusion: This first-in-man trial demonstrated a favourable PK profile of volasertib, with manageable toxicities. As expected, the most common events were haematological. Encouraging preliminary antitumour activity has been observed, supporting Plk inhibition as a therapeutic approach. Clinical development of volasertib in phase II monotherapy and combination trials is ongoing. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552127 Mon, 28 Nov 2011 05:00:00 +0100 5552127 http://www.medworm.com/index.php?rid=5494689&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008689%2Fabstract%3Frss%3Dyes Conclusions: The primary end-point of this study was met as >12 (15/38) patients could have stopped treatment early on the basis of the FDG PET–CT scan result. A FDG PET–CT evaluable response of SD or PD at 6weeks does predict future lack of response. No correlation was found between response and symptomatic response at either 6 or 12weeks. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494689 Mon, 28 Nov 2011 05:00:00 +0100 5494689 http://www.medworm.com/index.php?rid=5638190&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100863X%2Fabstract%3Frss%3Dyes Abstract: It can be difficult to identify endpoints that accurately reflect patient benefit in metastatic solid tumors. Overall survival (OS) is the gold standard although progression-free survival (PFS) is sometimes used as a surrogate for OS. Statistical modelling has suggested that the association between OS and PFS becomes weaker in diseases with longer survival post-progression (SPP). To evaluate these statistical hypotheses we determined the relationship between PFS and OS in control and experimental arms of randomised trials conducted in the last 10years, which have led to drug approval. Our data confirm that PFS is a poor surrogate for OS when SPP is long, but it is a better surrogate where SPP is short. In cancers with short SPP designing trials to show OS benefit is feasible and,... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638190 Thu, 24 Nov 2011 05:00:00 +0100 5638190 http://www.medworm.com/index.php?rid=5552128&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100829X%2Fabstract%3Frss%3Dyes Abstract: Background: The effect of zoledronic acid in breast cancer adjuvant therapy concerning improvement of patient survival has yet to be confirmed. We performed a meta-analysis of published and unpublished randomised controlled trials with the aim of accurate evaluation between clinical outcome and the association of the addition of zoledronic acid to adjuvant therapy.Methods: We searched PubMed (from 1966 to present) and online abstracts from the proceeding Annual Meetings of the American Society of Clinical Oncology (ASCO) (years 1992–2010) and online abstracts from San Antonio Breast Cancer Symposium (years 2004–2010). A total of five eligible studies including 3676 subjects and 3678 controls met our search criteria and were evaluated. Random and fixed-effects meta-analytical ... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552128 Mon, 21 Nov 2011 05:00:00 +0100 5552128 http://www.medworm.com/index.php?rid=5494684&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006113%2Fabstract%3Frss%3Dyes Conclusion: The scoring system was not sufficiently accurate to safely define a subset of patients who would be eligible for follow-up only and no additional treatment. These results demonstrate a lack of reproducibility in an external population. A multidisciplinary approach that correlates clinicopathological and mammographic features should be recommended for the management of these patients. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494684 Mon, 21 Nov 2011 05:00:00 +0100 5494684 http://www.medworm.com/index.php?rid=5552140&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007982%2Fabstract%3Frss%3Dyes Conclusion: This study demonstrated that lapatinib brings about deterioration of lipid profile and triggers hepatic toxicity mainly as sinusoidal injury with elevation in transaminase levels, especially ALT. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552140 Fri, 18 Nov 2011 05:00:00 +0100 5552140 http://www.medworm.com/index.php?rid=5552126&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007386%2Fabstract%3Frss%3Dyes Abstract: There has been a significant shift within oncology drug development away from empiric screening of cytotoxic compounds to the era of genomics and molecularly targeted agents. The drug development process is evolving with greater emphasis on proof-of-mechanism studies in both preclinical and early clinical development. The Methodology for the Development of Innovative Cancer Therapies (MDICT) Task Force, established as a forum for academic and pharmaceutical leaders to discuss methodological issues in targeted anticancer therapy development, met in March 2010 to review what were the minimal data required to make appropriate decisions about moving new targeted cancer agents from late preclinical development into phase I and from phase I into phase II trials. A number of specific qu... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552126 Fri, 18 Nov 2011 05:00:00 +0100 5552126 http://www.medworm.com/index.php?rid=5638189&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911008239%2Fabstract%3Frss%3Dyes Conclusions: No relevant toxicity with those therapeutic regimens was observed. Fatal outcome in three patients may have been related to corticosteroids. Cognitive function improved during treatment. However, median overall survival for all patients was only 4.9months (95% CI 2.3–5.7) and 1-year survival 25.4% (95% CI 15.4–37.0%). (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638189 Thu, 17 Nov 2011 05:00:00 +0100 5638189 http://www.medworm.com/index.php?rid=5552139&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007957%2Fabstract%3Frss%3Dyes Conclusion: The downward trend in the annual number of avoidable deaths reflects more an improvement in survival in England overall, rather than a narrowing of the deficit in cancer survival between poor and rich. The lack of any substantial change in the percentage of avoidable excess deaths highlights the persistent nature of the deficit in survival between affluent and deprived groups. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552139 Thu, 17 Nov 2011 05:00:00 +0100 5552139 http://www.medworm.com/index.php?rid=5494699&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007179%2Fabstract%3Frss%3Dyes Abstract: Glioblastoma multiforme (GBM) is a highly invasive and aggressive primary brain tumour in which loss of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a negative regulator of PI3K signalling, is a common feature. PTEN/PI3K/Akt signalling is involved in the regulation of proliferation, apoptosis and cell migration. Deregulation of PI3K signalling is considered an essential driver in gliomagenesis. However, the role of different PI3K isoforms in glioma is still largely unclear. Here we show that the catalytic PI3K isoform p110δ is consistently expressed at a high level in various glioma cell lines. We used small interfering RNA to selectively deplete p110δ and to determine its tumourigenic roles in PTEN-deficient cells. Interestingly, knockdown of p110δ decrea... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494699 Mon, 14 Nov 2011 05:00:00 +0100 5494699 http://www.medworm.com/index.php?rid=5457093&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007131%2Fabstract%3Frss%3Dyes Conclusions: Linifanib demonstrated clinically meaningful activity in patients with advanced RCC after sunitinib failure. At 0.25mg/kg/day, significant dose modifications were required. An alternative, fixed-dosing strategy is being evaluated in other trials. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457093 Mon, 14 Nov 2011 05:00:00 +0100 5457093 http://www.medworm.com/index.php?rid=5552132&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007878%2Fabstract%3Frss%3Dyes Abstract: Summary: Adjuvant interferon has modest activity in melanoma patients at high risk for relapse. Patient selection is important; stage and ulceration of the primary tumour are key prognostic factors.Methods: In this post hoc meta-analysis of European Organisation for Research and Treatment of Cancer (EORTC) trials 18952 (intermediate doses of interferon α-2b [IFN] versus observation in stage IIb-III patients) and 18991 (pegylated [PEG]-IFN versus observation in stage III patients), the predictive value of ulceration on the efficacy of IFN/PEG-IFN with regard to relapse-free survival (RFS), distant metastasis-free survival (DMFS), and overall survival (OS) was assessed in the overall population and in subgroups stratified by stage (IIb and III-N1 [microscopic nodal disease] and II... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552132 Mon, 07 Nov 2011 05:00:00 +0100 5552132 http://www.medworm.com/index.php?rid=5457097&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007192%2Fabstract%3Frss%3Dyes Conclusions: The terminally ill adolescent displays notable challenges to care providers and requires a holistic approach with the help of a multidisciplinary team. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457097 Fri, 04 Nov 2011 04:00:00 +0100 5457097 http://www.medworm.com/index.php?rid=5457098&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007271%2Fabstract%3Frss%3Dyes Conclusions: The logistically complex MINDACT trial is feasible in a multinational setting. The proportion of discordant patients, the potential reduction in CT by using the genomic signature and compliance to treatment assignment are in accordance with the trial hypotheses. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457098 Thu, 03 Nov 2011 04:00:00 +0100 5457098 http://www.medworm.com/index.php?rid=5494693&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007222%2Fabstract%3Frss%3Dyes Abstract: Objective: To describe the management of anaemia in 2009–2010 in France in patients with haematological malignancies (HM) or solid tumours (ST).Methods: Retrospective observational study in 57 centres, enrolling adult patients with HM or ST treated for an episode of anaemia (duration of the episode ⩾3months occurring in the last 12months).Results: 220 patients with ST (breast, 18%; lung, 18%) and 56 with HM (lymphoma, 60%) were included (median age, 68years; female, 53%). Mean haemoglobin level at anaemia diagnosis was 9.3±1.4g/dL ( (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494693 Wed, 02 Nov 2011 04:00:00 +0100 5494693 http://www.medworm.com/index.php?rid=5638188&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007337%2Fabstract%3Frss%3Dyes Abstract: Background: Strongly marked ideological positions on the impact of palliative care and limited hard data plague the debate on physician-assisted death.Methods: A national cross-sectional study on the requests to hasten death (RHD) was conducted among 789 French palliative care organisations. Data were collected for all patients with RHD encountered during year 2010. Data on patients’ characteristics, medical, psychological and social context, symptoms, nature of palliative management, patient’s evolution and palliative care team’s interpretation of the request were obtained.Findings: A majority of centres responded and 342 teams provided descriptions of 783 RHD, 476 by a patient, 258 by relatives or close friends and 49 by the nursing staff. Cancer was the most frequent pat... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638188 Mon, 31 Oct 2011 04:00:00 +0100 5638188 http://www.medworm.com/index.php?rid=5494688&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007350%2Fabstract%3Frss%3Dyes Conclusion: Routine epidermal growth factor receptor (EGFR) screening using diagnostic samples is fast and feasible even on samples with poor cellularity and DNA content. Mutations tend to occur in better-differentiated non-mucinous TTF1+ ADCs. Whether these histological criteria may be useful to select patients for EGFR testing merits further investigation. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494688 Mon, 31 Oct 2011 04:00:00 +0100 5494688 http://www.medworm.com/index.php?rid=5552137&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007349%2Fabstract%3Frss%3Dyes Conclusions: Temsirolimus administered weekly at the dose of 75mg/m2 did not meet the primary objective efficacy threshold in children with high-grade glioma, neuroblastoma or rhabdomyosarcoma; however, meaningful prolonged stable disease merits further evaluation in combination therapy. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552137 Fri, 28 Oct 2011 04:00:00 +0100 5552137 http://www.medworm.com/index.php?rid=5400259&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006083%2Fabstract%3Frss%3Dyes Abstract: Purpose: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cancers in Europe (RARECARE) provides estimates of the incidence, prevalence and survival of rare cancers in Europe based on a new and comprehensive list of these diseases.Materials and methods: RARECARE analysed population-based cancer registry (CR) data on European patients diagnosed from 1988 to 2002, with vital status information available up to 31st December 2003 (latest date for which most CRs had verified data). The mean population covered was about 162,000,000. Cancer incidence and survival rates for 1995–2002 and prevalence at 1st January 2003 were estimated.Results: Based on the RARECARE definition (incidence (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400259 Fri, 28 Oct 2011 04:00:00 +0100 5400259 http://www.medworm.com/index.php?rid=5347000&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006654%2Fabstract%3Frss%3Dyes Abstract: In September 2011 a unique high level summit on non-communicable diseases will be held in New York. For cancer as for many of the other chronic diseases this marks their first high level recognition. However, the reality of cancer control in middle and low income countries is and will be very different from the trajectory experienced by developed countries. This perspective seeks to critically examine the approach being taken, mapping pitfalls and presenting alternative solutions for an international cancer control policy. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347000 Wed, 26 Oct 2011 06:28:56 +0100 5347000 http://www.medworm.com/index.php?rid=5552135&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007313%2Fabstract%3Frss%3Dyes The objective of this paper is to summarise the scientific review of the application leading to approval in the EU. The detailed scientific assessment report and product information, including the summary of product characteristics (SmPC), are available on the European Medicines Agency (EMA) website (www.ema.europa.eu). (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552135 Wed, 26 Oct 2011 04:00:00 +0100 5552135 http://www.medworm.com/index.php?rid=5638186&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007167%2Fabstract%3Frss%3Dyes Conclusion: The outcome of CNS ATRT remains poor. However, the use of HDC provides encouraging results. GTR is a significant prognostic factor. The role of adjuvant radiation remains unclear. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638186 Mon, 24 Oct 2011 04:00:00 +0100 5638186 http://www.medworm.com/index.php?rid=5638185&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911007301%2Fabstract%3Frss%3Dyes Conclusions: Examining SLNs by close central sectioning alone (EORTC Protocol) misses a substantial number of metastases and underestimates the maximum metastasis diameter, leading to important changes in patient eligibility for various treatment protocols. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638185 Mon, 24 Oct 2011 04:00:00 +0100 5638185 http://www.medworm.com/index.php?rid=5552130&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006861%2Fabstract%3Frss%3Dyes Abstract: Background: Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). The neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, is associated with outcome in several cancer types.Aims: To study the association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival (PFS) and overall survival (OS) of patients treated with sunitinib for mRCC.Methods: We retrospectively studied an unselected cohort of patients with mRCC, who were treated with sunitinib. Logistic regression model was used to analyse response rate. Cox regression models were fitted to identify risk factors associated with PFS and OS. We investigated how pre-treatment NLR is associated with these clinical outcomes after adjusting for confoundi... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552130 Mon, 24 Oct 2011 04:00:00 +0100 5552130 http://www.medworm.com/index.php?rid=5494696&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100726X%2Fabstract%3Frss%3Dyes Abstract: Background: Risk of coronary heart disease (CHD) in cancer patients has not been thoroughly investigated. The aim of the present study was to examine whether there is an association between cancer and first hospitalisation for CHD.Methods: All individuals in Sweden with a diagnosis of cancer between 1st January 1987 and 31st December 2008 were followed for first hospitalisation for CHD. The reference population was the total population of Sweden without cancer. Standardised incidence ratios (SIRs) for CHD were calculated.Results: The overall CHD risk during the first 6months after diagnosis of cancer was 1.70 (95% confidence interval (95% CI) 1.66–1.75). For 26 of the 34 cancers studied, the risk of CHD was increased during the first 6months after diagnosis of cancer. The overa... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494696 Mon, 24 Oct 2011 04:00:00 +0100 5494696 http://www.medworm.com/index.php?rid=5552134&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006411%2Fabstract%3Frss%3Dyes Abstract: Background: In chronic myeloid leukaemia (CML), clonal evolution with resistance to tyrosine kinase inhibitors (TKIs) is often triggered by BCR/ABL1 mutations. However, in the context of the complex pro-oncogenic signalling networks which ultimately lead to clonal expansion and disease progression, the exact contribution of BCR/ABL1 mutants remains uncertain. Recent data indicate that detection of BCR/ABL1 mutant subclones does not permit prediction of their expansion dynamics and their potential to become drivers of resistant disease.Methods: To determine the patterns of clonal evolution and the distinct proliferation kinetics of individual BCR/ABL1 mutants during treatment, we employed ligase-dependent polymerase chain reaction (LD-PCR) analysis for quantitative surveillance of... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552134 Wed, 28 Sep 2011 04:00:00 +0100 5552134 http://www.medworm.com/index.php?rid=5400277&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100640X%2Fabstract%3Frss%3Dyes In this study, we have confirmed that the basal activity of the phospatidylinositol 3-kinase (PI3K)/JNK/activator protein 1 (AP-1) pathway promoted pancreatic cancer cell growth when stimulated by growth factors. Interestingly, although treatment with the PP2A inhibitors, cantharidin or okadaic acid (OA), amplified the PI3K-dependent activation of JNK, cell growth was repressed. We therefore hypothesised that a specific level of activity of the JNK pathway might be required to maintain the promitogenic function, as both repression and overactivation of JNK could inhibit cell proliferation. It was found that the JNK-dependent growth inhibition was independent of the activation of AP-1, but dependent on the repression of Akt. Although the PP2A inhibitors triggered overactivation of JNK and i... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400277 Wed, 28 Sep 2011 04:00:00 +0100 5400277 http://www.medworm.com/index.php?rid=5400268&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006642%2Fabstract%3Frss%3Dyes Abstract: Angiogenesis has been associated with disease progression in many solid tumours, however the statement that tumours need angiogenesis to grow, invade and metastasise seems no longer applicable to all tumours or to all tumour subtypes. Prognostic studies in pancreatic cancer are conflicting. In fact, pancreatic cancer has been suggested an example of a tumour in which angiogenesis is less essential for tumour progression.The aim of the present study was therefore to measure angiogenesis in two anatomically closely related however prognostically different types of pancreatic cancer, pancreatic head and periampullary cancer, and investigate its relation with outcome.Vessels were stained by CD31 on original paraffin embedded tissue from 206 patients with microscopic radical resection... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400268 Wed, 28 Sep 2011 04:00:00 +0100 5400268 http://www.medworm.com/index.php?rid=5638179&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006058%2Fabstract%3Frss%3Dyes The objectives of this study were to describe PA behaviour in the course of breast cancer and to identify factors associated with change in PA.Methods: 1,067 German postmenopausal breast cancer patients were asked about their PA behaviour before breast cancer diagnosis, during therapy and 1year after surgery. MET-hours per week (MET=metabolic equivalent) were calculated based on quantitative information about walking, bicycling for transportation purposes and sports by multiplying the average hours per week spent at each activity with an individual intensity score. Factors associated with change in MET·h/week in the course of breast cancer were identified using multiple linear regression.Results: Median PA decreased significantly during therapy from 36 to 14MET·h/week (p (Source: Europea... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638179 Mon, 19 Sep 2011 04:00:00 +0100 5638179 http://www.medworm.com/index.php?rid=5400274&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006101%2Fabstract%3Frss%3Dyes Abstract: Relative survival is a widely used measure of cancer patient survival, defined as the observed survival of the cancer patients divided by the expected survival of a comparable group from the general population, free from the cancer under study. In practise, expected survival is usually calculated from general population life tables. Such estimates are known to be biased since they also include mortality from the cancer patients, but the bias is ignored since mortality among individuals with a specific cancer is thought to constitute only a small proportion of total mortality. Using the computerised population registers that exist in Sweden we had the unique opportunity to calculate expected survival both including and excluding individuals with cancer, and thereby estimate the si... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400274 Mon, 19 Sep 2011 04:00:00 +0100 5400274 http://www.medworm.com/index.php?rid=5347003&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006046%2Fabstract%3Frss%3Dyes Conclusions: The combination of NPLD and docetaxel demonstrated high antitumour activity in a population of metastatic breast cancer patients exposed to adjuvant anthracyclines and showed an unexpected and unexplained 15% symptomatic left ventricular systolic dysfunction rate. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347003 Thu, 15 Sep 2011 04:00:00 +0100 5347003 http://www.medworm.com/index.php?rid=5347014&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005521%2Fabstract%3Frss%3Dyes This article has been removed: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This abstract has been removed at the request of the Editor-in-Chief and author because it contains a drug dosage error which could have serious health consequences. The abstract contained a dosage error for the drug, docetaxel. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347014 Fri, 09 Sep 2011 04:00:00 +0100 5347014 http://www.medworm.com/index.php?rid=5400270&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005508%2Fabstract%3Frss%3Dyes Abstract: Background: Axitinib (AG-013736) is an oral, selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, 2 and 3. This phase II study investigated axitinib efficacy, safety and biomarkers in Japanese patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).Patients and methods: In an open-label, multicentre study, 64 patients received an axitinib starting dose of 5mg twice daily.Results: Objective response rate (ORR) was 50.0% and median progression-free survival (PFS) was 11.0months per independent review committee. Common treatment-related adverse events were hypertension (84%; 70% grade ⩾3), hand–foot syndrome (75%; 22% grade ⩾3) and diarrhoea (64%; 5% grade ⩾3). Eighteen patients (28%) developed proteinuria ⩾2g/24h and r... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400270 Mon, 05 Sep 2011 04:00:00 +0100 5400270 http://www.medworm.com/index.php?rid=5208014&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006162%2Fabstract%3Frss%3Dyes (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208014 Thu, 01 Sep 2011 04:00:00 +0100 5208014 http://www.medworm.com/index.php?rid=5273358&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005910%2Fabstract%3Frss%3Dyes The authors would like to correct the name of the fourth author, which was stated as Burkhard von Raden in their published article. The corrected name, Burkhard H.A. von Raden, is given above. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273358 Wed, 31 Aug 2011 04:00:00 +0100 5273358 http://www.medworm.com/index.php?rid=5208015&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911006022%2Fabstract%3Frss%3Dyes (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208015 Mon, 29 Aug 2011 04:00:00 +0100 5208015 http://www.medworm.com/index.php?rid=5494687&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005089%2Fabstract%3Frss%3Dyes Conclusion: The differences in the magnitudes of both the hazard ratios and the absolute excess deaths within resected patients and all NSCLC patients suggests that lung cancer survival in England could plausibly increase if a larger proportion of patients underwent surgical resection. Carefully designed research into the possible benefit of increasing resection rates is indicated. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494687 Fri, 26 Aug 2011 04:00:00 +0100 5494687 http://www.medworm.com/index.php?rid=5143385&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005302%2Fabstract%3Frss%3Dyes (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5143385 Sat, 20 Aug 2011 13:16:20 +0100 5143385 http://www.medworm.com/index.php?rid=5494690&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005053%2Fabstract%3Frss%3Dyes Conclusions: We conclude that socioeconomic disparities in the management and mortality in men with high risk prostate cancer exist also within the setting of a National Health Care System aiming to provide care on equal terms to all residents. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494690 Thu, 18 Aug 2011 04:00:00 +0100 5494690 http://www.medworm.com/index.php?rid=5400276&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100503X%2Fabstract%3Frss%3Dyes In this study, the authors examined a novel small molecule inhibitor of ALK5, 3-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methylamino)benzonitrile (EW-7195) to determine if it has potential for cancer treatment. The inhibitory effects of EW-7195 on TGF-β-induced Smad signaling and epithelial-to-mesenchymal transition (EMT) were investigated in mammary epithelial cells using luciferase reporter assays, immunoblotting, confocal microscopy and wound healing assays. In addition, the suppressive effects of EW-7195 on mammary cancer metastasis to lung were examined using a Balb/c xenograft and MMTV/cNeu transgenic mice model system. The novel ALK5 inhibitor, EW-7195, inhibited the TGF-β1-stimulated transcriptional activations of p3TP-Lux and pCAGA12-Luc... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400276 Thu, 18 Aug 2011 04:00:00 +0100 5400276 http://www.medworm.com/index.php?rid=5273357&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005028%2Fabstract%3Frss%3Dyes Abstract: Although Epidermal growth factor receptor (EGFR) is particularly important in the pathogenesis of head and neck squamous cell carcinomas (HNSCCs), conflicting data have been reported on the correlation between EGFR copy number and survival and the association between EGFR copy number and protein expression. Anatomical site of the tumour in HNSCCs may likely contribute to the discordance of the above points as EGFR expression may differ between the sub-sites of HNSCCs. Thus, in this study, we focused on oral tongue squamous cell carcinomas (OTSCCs). To investigate the association between EGFR copy number alteration and overexpression and to determine which is the more reliable prognostic indicator, Fluorescence in situ hybridisation (FISH) and immunohistochemical staining (IHC) we... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273357 Thu, 18 Aug 2011 04:00:00 +0100 5273357 http://www.medworm.com/index.php?rid=5273344&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005041%2Fabstract%3Frss%3Dyes Abstract: This phase I study (ClinicalTrials.gov ID: NCT00424632) evaluated the safe dose, pharmacokinetics, and pharmacodynamics of the aurora kinase A and B inhibitor, PF-03814735. Patients with advanced solid tumours received oral, once-daily (QD) PF-03814735 on Schedule A: days 1–5 (5–100mg); or Schedule B: days 1–10 (40–60mg) of 21-day cycles. Fifty-seven patients were treated: 32 and 25 on Schedules A and B, respectively. Dose-limiting toxicities were: febrile neutropenia (Schedule A); and increased levels of aspartate amino transferase, left ventricular dysfunction, and prolonged low-grade neutropenia (Schedule B). Maximum tolerated doses were 80mg QD (Schedule A) and 50mg QD (Schedule B). Common treatment-related adverse events were mainly mild to moderate and included diar... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273344 Thu, 18 Aug 2011 04:00:00 +0100 5273344 http://www.medworm.com/index.php?rid=5400267&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004989%2Fabstract%3Frss%3Dyes Conclusions: The 7th AJCC staging system provided better prognostic power than the 6th for patients with HCC, but not better than that of the BCLC system. Thus, the 7th AJCC staging system should be applied cautiously in patients with advanced HCC because of its low prognostic power in advanced stages. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400267 Thu, 11 Aug 2011 04:00:00 +0100 5400267 http://www.medworm.com/index.php?rid=5347005&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004977%2Fabstract%3Frss%3Dyes This study used a population-based cohort of 3866 patients who underwent surgery for oesophageal or gastric cancer between 1998 and 2008 with follow-up until December 2008.Results: Hospital volume ranged from 1 to 68 cases/year. Overall, 5-year survival was 27%. Increasing age and advanced stage of disease were independently correlated with shorter survival. High hospital volume was significantly and independently correlated with improved 30-day mortality postoperatively (P (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347005 Thu, 11 Aug 2011 04:00:00 +0100 5347005 http://www.medworm.com/index.php?rid=5400264&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911002073%2Fabstract%3Frss%3Dyes Abstract: Cell cycle checkpoint kinase 2 (CHEK2) gene has been inconsistently associated with colorectal cancer (CRC), particularly the 1100delC variant. To generate large-scale evidence on whether the CHEK2 1100delC variant is associated with CRC susceptibility we have conducted a meta-analysis. Data were collected from the following electronic databases: PubMed, Excerpta Medica Database and Chinese Biomedical Literature Database, with the last report up to November 2010. The odds ratio (OR) and its 95% confidence interval (95% CI) were used to assess the strength of association. We evaluated the contrast of carriers versus non-carriers. Meta-analysis was performed in a fixed/random effect model by using the software Review Manager 4.2. A total of six studies including 4194 cases and 10,0... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400264 Tue, 02 Aug 2011 04:00:00 +0100 5400264 http://www.medworm.com/index.php?rid=5638182&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004928%2Fabstract%3Frss%3Dyes Conclusion: Everolimus is well tolerated in patients with mRCC and demonstrates a favourable risk–benefit ratio. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638182 Mon, 01 Aug 2011 04:00:00 +0100 5638182 http://www.medworm.com/index.php?rid=5400266&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004667%2Fabstract%3Frss%3Dyes Abstract: Purpose: Obesity is associated with an increased risk of development and recurrence of colorectal cancer. However, the role of obesity in advanced colorectal cancer (ACC) patients is unknown. We investigated the effect of body mass index (BMI) on overall survival (OS) in ACC patients receiving systemic treatment in two large phase III studies (CAIRO and CAIRO2).Patients and methods: Treatment data were obtained and analysed from 796 ACC patients who were treated with chemotherapy in the CAIRO study, and from 730 ACC patients who were treated with chemotherapy plus targeted therapy in the CAIRO2 study. Baseline height and weight were used to assign patients to one of the following BMI categories: A ( (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400266 Mon, 01 Aug 2011 04:00:00 +0100 5400266 http://www.medworm.com/index.php?rid=5273353&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004734%2Fabstract%3Frss%3Dyes Conclusions: Despite its premature closure, this trial confirms previous evidence that consolidation gefitinib is safe and improves PFS. However, no difference in OS was observed in this study (NCT00091156). (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273353 Mon, 01 Aug 2011 04:00:00 +0100 5273353 http://www.medworm.com/index.php?rid=5109050&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911005132%2Fabstract%3Frss%3Dyes (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5109050 Sun, 31 Jul 2011 23:00:00 +0100 5109050 http://www.medworm.com/index.php?rid=5208025&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004904%2Fabstract%3Frss%3Dyes Abstract: Current developments in systemic therapies for melanoma are spectacular. Over the last 40years no one drug or combination of drugs demonstrated any impact on survival in metastatic melanoma. In contrast, in 2011 a number of new drugs will be approved.In 2011 immunomodulation with ipilimumab, a monoclonal antibody targeting the ligand CTLA-4, has been approved for patients with advanced melanoma in first- and second-line treatment by the Food and Drug Administration (FDA) and in second-line treatment by the European Medicines Agency (EMA). Also in 2011, a significant survival benefit of the combination of ipilimumab with dacarbazine compared with dacarbazine alone for first-line treatment was reported. Other monoclonal antibodies targeting T-cell ligands, such as programmed death-... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208025 Fri, 29 Jul 2011 04:00:00 +0100 5208025 http://www.medworm.com/index.php?rid=5273354&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004953%2Fabstract%3Frss%3Dyes Conclusions: Our findings support the hypothesis that, although pain was not the main indication for PS, pain and its treatment might have been primarily related to the need for palliative sedation in this patient cohort. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273354 Thu, 28 Jul 2011 04:00:00 +0100 5273354 http://www.medworm.com/index.php?rid=5494692&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004941%2Fabstract%3Frss%3Dyes Abstract: Background: Mutations of NRAS and BRAF have been described in Caucasian melanomas. However, the status and the clinical significance of BRAF and NRAS mutations in the Asian population have not been investigated on a large scale.Methods: Melanoma samples (n=432) were analysed for mutations in exons 11 and 15 of the BRAF gene, and exons 1 and 2 of the NRAS gene in genomic DNA by polymerase chain reaction (PCR) amplification and Sanger sequencing. Mutations of BRAF and NRAS genes were correlated to clinicopathologic features and prognosis of the patients.Results: The incidence of somatic mutations within the BRAF and NRAS genes was 25.5% (110/432) and 7.2% (31/432), respectively. Among the 110 patients with BRAF mutations, 98 patients (89.1%) had V600E mutations. Melanomas without c... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494692 Tue, 26 Jul 2011 04:00:00 +0100 5494692 http://www.medworm.com/index.php?rid=5457092&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100493X%2Fabstract%3Frss%3Dyes Conclusions: Our results show that FP results are common adverse effects in PC screening, as they affect at least one in six screened men. False-positive men are more prone to be diagnosed with PC but are also likely to have consistently high PSA levels. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457092 Tue, 26 Jul 2011 04:00:00 +0100 5457092 http://www.medworm.com/index.php?rid=5457090&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004655%2Fabstract%3Frss%3Dyes Abstract: Hepatic arterial infusion (HAI) selectively achieves high drug exposure of liver metastases from colorectal cancer. Such pharmacologic advantage has doubled the response rate of liver metastases on fluoropyrimidines (FP) delivered as HAI rather than intravenously, in a meta-analysis of randomised clinical trials (RCT). However, the improvement in antitumour efficacy did not consistently translate into any significant survival advantage across all randomised studies. However, the results of this meta-analysis should be cautiously interpreted due to the heterogeneity of the studies, inadequate study designs, obsolete therapy and high rate of early treatment discontinuation due to HAI technical failures or hepato-biliary toxicity. Most studies actually were performed before year 200... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457090 Mon, 25 Jul 2011 04:00:00 +0100 5457090 http://www.medworm.com/index.php?rid=5400271&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004746%2Fabstract%3Frss%3Dyes Conclusion: Our findings suggest that retreatment with erlotinib is an option for patients with NSCLC who initially benefited from previous EGFR-TKI treatment and progressed after standard cytotoxic chemotherapy. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400271 Mon, 25 Jul 2011 04:00:00 +0100 5400271 http://www.medworm.com/index.php?rid=5347004&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004643%2Fabstract%3Frss%3Dyes Conclusions: Treatment for CRC reduces cellular immunity and potentially puts HIV patients at risk of opportunistic infections; knowledge of HIV status prior to starting treatment is essential. This risk may be reduced by concomitant HAART and prophylaxis. Clinicians managing CRC should consider screening patients for HIV before starting chemotherapy or radiotherapy. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347004 Fri, 22 Jul 2011 04:00:00 +0100 5347004 http://www.medworm.com/index.php?rid=5494698&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004722%2Fabstract%3Frss%3Dyes Abstract: Development of hepatocellular carcinoma (HCC) is a complex and progressive disease that involves cycles of liver cell death, inflammation, and tissue regeneration/remodelling. Chemokines and chemokine receptors play numerous and integral roles in the disease progression of HCC. Here we investigated the novel chemokine receptor CXCR7/RDC1 in HCC progression, its two known ligands CXCL12 and CXCL11, as well as the other CXCL12 receptor, CXCR4. Our results show that in a cohort of 408 human HCCs, CXCR7 and CXCL11 were significantly higher in tumours compared to normal liver controls (5- and 10-fold, respectively). Immunohistochemical (IHC) staining on human HCC sections confirmed that both CXCL11 and CXCR7 were much higher in cancer tissues. Furthermore, IHC staining revealed that C... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494698 Thu, 21 Jul 2011 04:00:00 +0100 5494698 http://www.medworm.com/index.php?rid=5494683&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004680%2Fabstract%3Frss%3Dyes Conclusion: This regimen of metronomic capecitabine displayed good activity and excellent tolerability in MBC patients, including those who had previously received the drug at standard doses. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494683 Wed, 20 Jul 2011 04:00:00 +0100 5494683 http://www.medworm.com/index.php?rid=5457088&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004679%2Fabstract%3Frss%3Dyes Abstract: Acute radiation skin reactions (ARSR) are a major problem in curative radiotherapy (RT). A number of studies have failed to show a positive effect of different skin care products to reduce or prevent ARSR. The aims for this study were to describe frequency and severity of ARSR in patients with breast cancer undergoing adjuvant RT and to test the suitability in clinical use of two assessment instruments.A majority (93%) of the 93 patients with breast cancer included in this study developed ARSR, most of them mild reactions. Low scores for pain and itching (VAS) were reported. ARSR were assessed using the modified version of RTOG/EORTC acute radiation morbidity scoring criteria and the World Health Organisation (WHO) grading system for acute and subacute toxicity by two independent... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457088 Wed, 20 Jul 2011 04:00:00 +0100 5457088 http://www.medworm.com/index.php?rid=5347013&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004692%2Fabstract%3Frss%3Dyes In this study we investigated the expression level and the role of miR-21 in MB cell migration. miR-21 was found to be up-regulated, compared to normal cerebellum, in 29/29 MB primary samples and 6/6 MB-derived cell lines. Inverse correlation was observed between miR-21 expression and the metastasis suppressor PDCD4, while miR-21 repression increased the release of PDCD4 protein, suggesting negative regulation of PDCD4 by miR-21 in MB cells. Anti-miR-21 decreased protein expression of the tumour cell invasion mediators MAP4K1 and JNK, which are also known to be negatively regulated by PDCD4, and down-regulated integrin protein that is essential for MB leptomeningeal dissemination. Moreover miR-21 knockdown in MB cells increased the expression of two eminent negative modulators of cancer ce... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347013 Wed, 20 Jul 2011 04:00:00 +0100 5347013 http://www.medworm.com/index.php?rid=5347011&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004758%2Fabstract%3Frss%3Dyes Conclusion: The SAG patients reported a trend of more pain, had significantly more dropouts and three SAEs, which indicate that the SAG strategy should not replace the 3DS when switching from high doses of morphine or oxycodone to methadone. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347011 Wed, 20 Jul 2011 04:00:00 +0100 5347011 http://www.medworm.com/index.php?rid=5208016&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004370%2Fabstract%3Frss%3Dyes Pathologists cater to their clinical partners. The information included in pathology reports corresponds to their needs to treat patients according to the latest standards. To that aim, reporting standards have been developed in a combined effort of pathologists and clinicians and enormous efforts are made to adhere to these standards and to keep them up to date. In addition to that, pathologists adapt to specific requests by their clinical partners, motivated either by specific treatment options (i.e. K-ras mutational status for colorectal carcinomas), by academic activities (i.e. p53 signatures in prophylactically resected fallopian tubes), or by local particularities (i.e. locally divergent «standards» for what is considered a positive, a close or a negative margin for in situ or inva... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208016 Mon, 18 Jul 2011 04:00:00 +0100 5208016 http://www.medworm.com/index.php?rid=5400260&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004151%2Fabstract%3Frss%3Dyes Conclusions: RECIST evaluation of tumour response depends on the natural history of the tumours and poorly measures the impact of treatment on the kinetics of tumour growth. Integrating pre-treatment GR evaluations could substantially improve the assessment of treatment efficacy in drug development. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400260 Fri, 15 Jul 2011 04:00:00 +0100 5400260 http://www.medworm.com/index.php?rid=5347002&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004229%2Fabstract%3Frss%3Dyes Conclusions: In this exploratory sub-analysis in AVADO, bevacizumab plus docetaxel showed efficacy in elderly patients similar to the overall study population. There were no unexpected safety signals in patients aged 65years or older. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347002 Fri, 15 Jul 2011 04:00:00 +0100 5347002 http://www.medworm.com/index.php?rid=5494682&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004291%2Fabstract%3Frss%3Dyes Conclusions: MAGE-A antigen defines a very aggressive subgroup of TNBC; particularly in the absence of immune infiltration in the tumour microenvironment. These observations suggest a therapeutic hypothesis; TNBC with MAGE-A expression may benefit the most from further augmentation of the immune response. Novel immune stimulatory drugs such as (anti-cytotoxic T-lymphocyte antigen-4 CTLA-4) directed therapies provide a realistic opportunity to directly test this hypothesis in the clinic. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494682 Mon, 11 Jul 2011 04:00:00 +0100 5494682 http://www.medworm.com/index.php?rid=5494681&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004242%2Fabstract%3Frss%3Dyes Abstract: Aim of the study: Clinical practice guidelines (CPG) are an appropriate method to optimise routine clinical care. Numerous CPGs for the diagnosis and treatment of breast cancer have been developed by national health institutions or medical societies. While a comparison of methodological criteria has been undertaken before, it is unknown whether these CPGs differ in their actual treatment recommendations.Methods: We included national breast cancer CPGs from the USA, Canada, Australia, the UK, and Germany that satisfy internationally recognised methodological criteria and are in widespread use in daily clinical care. Treatment recommendations for adjuvant invasive breast cancer including surgery, radiation, endocrine therapy, chemotherapy and anti-HER2-therapy were compared.Results... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494681 Mon, 11 Jul 2011 04:00:00 +0100 5494681 http://www.medworm.com/index.php?rid=5457099&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004357%2Fabstract%3Frss%3Dyes Abstract: Photodynamic therapy (PDT) is an approved therapeutic procedure that exerts cytotoxic activity towards tumour cells by irradiating photosensitisers with light exposure to produce reactive oxygen species (ROS). In the current study, we have observed that there is an additional production of intracellular ROS during low dose PDT. A mitochondrial respiration-deficient cell line (ρ0 cells) was investigated to determine the involvement of electron transfer chain (ETC). The production of ROS was significantly different between ASTC-a-1 and ρ0ASTC-a-1 cells after an identical PDT treatment. Yet, with an increasing Photofrin dose, the difference gradually diminished. Pretreatment of the ASTC-a-1 cells with the ETC inhibitor rotenone lead the corresponding ROS production to a similar le... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457099 Mon, 11 Jul 2011 04:00:00 +0100 5457099 http://www.medworm.com/index.php?rid=5400263&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100431X%2Fabstract%3Frss%3Dyes Abstract: Background: Racial disparities in breast cancer outcomes are attributed to differences in baseline tumour characteristics and biology, stage, age, ethnic background and socioeconomic factors. However, little is known about racial differences in treatment-related toxicities. We hypothesised that racial/ethnic differences result in differential tolerance to chemotherapy potentially, leading to compromised dose intensity/density of chemotherapy in patients with early-stage breast cancer.Methods: Data were collected from patients treated at five international centers for early breast cancer with the same adjuvant/neoadjuvant chemotherapy (FEC 100: fluorouracil 500mg/m2, epirubicin 100mg/m2, and cyclophosphamide 500mg/m2,every 21d for 3–6 cycles). Toxicities were assessed by first e... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400263 Mon, 11 Jul 2011 04:00:00 +0100 5400263 http://www.medworm.com/index.php?rid=5400262&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004308%2Fabstract%3Frss%3Dyes Conclusion: Contrary to commonly held opinions, we did not observe an increased prevalence of meningiomas in cancer survivors. Breast cancer survivors previously treated with chemotherapy are more likely to develop pituitary adenomas than persons without a history of cancer and chemotherapy treatment. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400262 Mon, 11 Jul 2011 04:00:00 +0100 5400262 http://www.medworm.com/index.php?rid=5400261&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004230%2Fabstract%3Frss%3Dyes Abstract: Background: The risk of recurrence following surgery in women with early breast cancer varies, depending upon prognostic factors. Adjuvant chemotherapy reduces this risk; however, increasingly effective regimens are associated with higher costs and toxicity profiles, making it likely that different regimens may be cost-effective for women with differing prognoses. To investigate this we performed a cost-effectiveness analysis of four treatment strategies: (1) no chemotherapy, (2) chemotherapy using cyclophosphamide, methotrexate, and fluorouracil (CMF) (a first generation regimen), (3) chemotherapy using Epirubicin-CMF (E-CMF) or fluorouracil, epirubicin, and cyclophosphamide (FEC60) (a second generation regimens), and (4) chemotherapy with FEC60 followed by docetaxel (FEC-D) (a ... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400261 Mon, 11 Jul 2011 04:00:00 +0100 5400261 http://www.medworm.com/index.php?rid=5347009&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003996%2Fabstract%3Frss%3Dyes Conclusion: Broad assessment of general well-being, self-rated as global quality of life, appears to be a better predictor of cancer risk than more specific information on social relations and health. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347009 Mon, 11 Jul 2011 04:00:00 +0100 5347009 http://www.medworm.com/index.php?rid=5273350&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003960%2Fabstract%3Frss%3Dyes Abstract: Background: The value of second-line therapy for metastatic gastric cancer is unclear. So far there are no randomised phase III data comparing second-line chemotherapy to best supportive care (BSC). In this prospective, multicenter, open label, randomised phase III study we compared irinotecan to BSC to evaluate the impact on survival of second-line chemotherapy.Methods: Eligible patients (pts) had metastatic or locally advanced gastro-oesophageal junction or gastric adenocarcinoma, objective tumour progression during or within 6months after first-line chemotherapy and ECOG performance status 0–2. Stratification for time of progression after first-line therapy, ECOG PS and pretreatment secured even distribution of important prognostic factors.Treatment: Arm A: Irinotecan 250mg/... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273350 Mon, 11 Jul 2011 04:00:00 +0100 5273350 http://www.medworm.com/index.php?rid=5273347&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100428X%2Fabstract%3Frss%3Dyes Conclusion: Hepatectomy is rarely performed for BCLM but the studies described in this review indicate consistent results with superior 5-year survival for selected patients with isolated liver metastases and in those with well controlled minimal extrahepatic disease. To evaluate its efficacy and control for selection bias, a randomised trial of standard chemotherapy with or without hepatectomy for BCLM is warranted. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273347 Mon, 11 Jul 2011 04:00:00 +0100 5273347 http://www.medworm.com/index.php?rid=5273346&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004254%2Fabstract%3Frss%3Dyes Conclusions: Final overall survival analysis of the GBG-26 study did not demonstrate a significant survival benefit for treatment beyond progression with trastuzumab. However, in a post-hoc analysis, patients receiving anti-HER2 treatment as 3rd line therapy showed a better post-progression survival than those not receiving this targeted treatment. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273346 Mon, 11 Jul 2011 04:00:00 +0100 5273346 http://www.medworm.com/index.php?rid=5109054&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004217%2Fabstract%3Frss%3Dyes Conclusion: Our results suggest that c-myc amplification is significantly associated with a high pCR rate to P-FEC in breast tumours, especially in ER-positive tumours. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5109054 Sun, 10 Jul 2011 23:00:00 +0100 5109054 http://www.medworm.com/index.php?rid=5552136&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100400X%2Fabstract%3Frss%3Dyes Conclusions: Arm anthropometry in children with cancer is a sensitive measure of nutritional status. Since malnutrition at diagnosis was related to important clinical outcomes, an opportunity exists to devise simple, cost-effective nutritional interventions in such children that may enhance their prospects for survival. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5552136 Thu, 07 Jul 2011 04:00:00 +0100 5552136 http://www.medworm.com/index.php?rid=5273345&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004199%2Fabstract%3Frss%3Dyes Conclusions: Baseline CEC, in particular CD34+CEC, counts and the CD34 positive rate might be useful for the prediction of treatment response of preoperative chemotherapy in patients with operable breast cancer. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273345 Thu, 07 Jul 2011 04:00:00 +0100 5273345 http://www.medworm.com/index.php?rid=5208017&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004187%2Fabstract%3Frss%3Dyes Abstract: Neoadjuvant chemotherapy (NAC) has become a widely accepted method of sequencing systemic therapy for breast cancer treatment. While ‘response to chemotherapy’ in the neoadjuvant setting has been utilised to predict prognosis, the published data are inconsistent. The present meta-analysis was conducted to determine whether the pathologic response to NAC predicts for outcomes. Papers were selected from the PubMed database based on defined inclusion and exclusion criteria. Parameters such as number/percentage of patients having pCR and outcome statistics (i.e. overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS)) were collected. The analysis included 16 studies with 3776 patients. The summary odds ratio (OR) estimating the association of OS with pCR w... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208017 Thu, 07 Jul 2011 04:00:00 +0100 5208017 http://www.medworm.com/index.php?rid=5457091&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004278%2Fabstract%3Frss%3Dyes Abstract: Background: There is little data on the survival of elderly patients with stage III non-small cell lung cancer (NSCLC).Methods: Patients with stage III NSCLC in the Netherlands Cancer Registry/Limburg from January 1, 2002 to December 31, 2008 were included.Findings: One thousand and two patients with stage III were diagnosed, of which 237 were 75years or older. From 228 patients, co-morbidity scores were available. Only 33/237 patients (14.5%) had no co-morbidities, 195 (85.5%) had one or more important co-morbidities, 60 (26.3%) two or more co-morbidities, 18 (7.9%) three or more co-morbidities and 2 patients (0.9%) suffered from four co-morbidities. Forty-eight percent were treated with curative intent. No significant difference in Charlson co-morbidity, age or gender was found... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457091 Wed, 06 Jul 2011 04:00:00 +0100 5457091 http://www.medworm.com/index.php?rid=5347007&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004333%2Fabstract%3Frss%3Dyes Abstract: We conducted a meta-analysis of prospective studies to summarise the epidemiologic evidence regarding the association of body mass index (BMI) with non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) incidence and NHL mortality. Pertinent studies were identified by searching PubMed (1966–May 2011) and the reference lists of retrieved articles. For each study, we estimated a relative risk (RR) for a 5kg/m2 increase in BMI. A random-effects model was used to combine the RR estimates from individual studies. The summary RRs for a 5kg/m2 increase in BMI were 1.07 (95% confidence intervals (CI), 1.04–1.10) for NHL incidence (16 studies, n=17,291 cases) and 1.14 (95% CI, 1.04–1.26) for NHL mortality (five studies, n=3407 cases). BMI was significantly positively associate... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347007 Wed, 06 Jul 2011 04:00:00 +0100 5347007 http://www.medworm.com/index.php?rid=5273351&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004011%2Fabstract%3Frss%3Dyes Conclusions: To enable reasonable treatment decisions and avoid unnecessary morbidity, treatment in specialised centres should be intended at any time. Clinical studies performed by several study groups on an international level are urgently needed to further improve therapy. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273351 Wed, 06 Jul 2011 04:00:00 +0100 5273351 http://www.medworm.com/index.php?rid=5347006&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004059%2Fabstract%3Frss%3Dyes Abstract: The aim of the present study was to evaluate the potential predictive value of histology in non-small cell lung cancer (NSCLC) treated with curatively intended radiotherapy. In a collaborative effort among all the Swedish Oncology Departments, clinical data were collected for 1146 patients with a diagnosed non-small cell lung cancer subjected to curatively intended irradiation (⩾50Gy) during the years 1990 to 2000. The included patients were identified based on a manual search of all medical and radiation charts at the oncology departments from which the individual patient data were collected. Only patients who did not have a histological diagnosis date and death date/last follow-up date were excluded (n=141). Among the 1146 patients with non-small cell carcinoma eligible for a... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347006 Tue, 05 Jul 2011 04:00:00 +0100 5347006 http://www.medworm.com/index.php?rid=5457096&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004175%2Fabstract%3Frss%3Dyes This study compared definitive radiochemotherapy to surgery followed by radio(chemo)therapy. Forty-four patients treated with radiochemotherapy were matched to 88 patients receiving surgery plus radio(chemo)therapy. Groups were matched 1:2 for eight factors including age, gender, performance status, tumour site, histologic grade, T-/N-category and AJCC stage. Groups were compared for loco-regional control, metastases-free survival, overall survival and toxicity. Two-year loco-regional control rates were 75% after surgery plus radio(chemotherapy) and 66% after radiochemotherapy (p=0.39). Metastases-free survival rates were 76% and 77%, respectively (p=0.76). Overall survival rates were 67% and 63%, respectively (p=0.95). During follow up, 60% and 9% of the patients, respectively, received a... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457096 Mon, 04 Jul 2011 04:00:00 +0100 5457096 http://www.medworm.com/index.php?rid=5400275&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911002243%2Fabstract%3Frss%3Dyes Abstract: Introduction: Components of the systemic inflammatory response, combined to form inflammation-based prognostic scores (modified Glasgow Prognostic Score (mGPS), Neutrophil Lymphocyte Ratio (NLR), Platelet Lymphocyte Ratio (PLR), Prognostic Index (PI), Prognostic Nutritional Index (PNI)) have been associated with cancer specific survival. The aim of the present study was to compare the prognostic value of these scores.Methods: Patients (n=27,031) who had an incidental blood sample taken between 2000 and 2007 for C-reactive protein, albumin, white cell, neutrophil, lymphocyte and platelet counts, as well as a diagnosis of cancer (Scottish Cancer Registry) were identified. Of this group 8759 patients who had been sampled within two years following their cancer diagnosis were studied... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400275 Mon, 04 Jul 2011 04:00:00 +0100 5400275 http://www.medworm.com/index.php?rid=5347012&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003972%2Fabstract%3Frss%3Dyes Abstract: Pemetrexed is a clinically available anti-folate therapeutic agent used in combination with cisplatin for the management of patients with malignant pleural mesothelioma and advanced non-small cell lung cancer. Pemetrexed inhibits three enzymes in purine and pyrimidine synthesis necessary for precursor DNA nucleotides which in turn disrupts growth and survival of normal and cancer cells. The mechanism by which pemetrexed induces apoptosis remains largely uncharacterised. In the current study, we examined the downstream effect of pemetrexed in inducing apoptosis in lung cancer cells. We showed that pemetrexed induced apoptosis via up-regulation of Death Receptor 5 (DR5), an important death receptor for tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL). In addit... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347012 Mon, 04 Jul 2011 04:00:00 +0100 5347012 http://www.medworm.com/index.php?rid=4998516&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911004424%2Fabstract%3Frss%3Dyes (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=4998516 Thu, 30 Jun 2011 23:00:00 +0100 4998516 http://www.medworm.com/index.php?rid=5400269&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003716%2Fabstract%3Frss%3Dyes This study investigates the pituitary-Leydig cell axis in patients with stage I testicular germ cell cancer (TGCC) followed with surveillance only, in order to evaluate the risk of Leydig cell dysfunction one year after orchiectomy.Patients and methods: A retrospective evaluation of reproductive hormones in patients with unilateral stage I TGCC (N=72) without relapse diagnosed between 1990 and 2008. A group of healthy males (N=706) served as controls.Results: Before orchiectomy there were no significant differences in luteinizing hormone (LH) and testosterone (T) levels between human chorionic gonadotropin (hCG)-negative patients and controls, although 33% of the patients were outside the 97.5 percentile when using bivariate LH/T evaluation. At 1-year follow-up there was a significant incr... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400269 Mon, 27 Jun 2011 04:00:00 +0100 5400269 http://www.medworm.com/index.php?rid=5347008&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003753%2Fabstract%3Frss%3Dyes Conclusion: Meta-analysis in patients with localised high-grade osteosarcoma shows that 3-drug regimens, for example MAP are the most efficacious drug regimens. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347008 Mon, 27 Jun 2011 04:00:00 +0100 5347008 http://www.medworm.com/index.php?rid=5494694&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003741%2Fabstract%3Frss%3Dyes Conclusions: This study demonstrated that multi-agent chemotherapy alone is insufficient treatment for patients with mediastinal and stage IV disease. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494694 Thu, 23 Jun 2011 04:00:00 +0100 5494694 http://www.medworm.com/index.php?rid=5457095&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003765%2Fabstract%3Frss%3Dyes Conclusion: With fifteen strict regional MPNSTs in the fourteen years since our previous population study an annual incidence of above 1 per 1000 NF1 patients has now been maintained over a 27-year period. No significant increase in risk of MPNST in females compared to males was found, though the difference in survival is intriguing. Male survival is particularly poor with (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457095 Thu, 23 Jun 2011 04:00:00 +0100 5457095 http://www.medworm.com/index.php?rid=5457094&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003698%2Fabstract%3Frss%3Dyes Abstract: Wilms tumour (WT) is a paediatric kidney tumour, composed of blastemal, epithelial and stromal cells, with a relapse rate of approximately 15%. Long-term survival for patients with relapse remains approximately 50%. Current clinical and molecular research is directed towards identifying prognostic factors to define the minimal and intensive therapy for successful treatment of children with low and high risk of relapse, respectively. Blastemal component presents a high level of aggressiveness and responsiveness to chemotherapy. To identify molecular prognostic markers that are predictive of chemotherapy sensitivity in tumour relapse, blastemal-enriched samples from stage III and IV WT, from patients with relapse or without relapse, were analysed for 4608 human genes immobilised on... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457094 Thu, 23 Jun 2011 04:00:00 +0100 5457094 http://www.medworm.com/index.php?rid=5347010&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003686%2Fabstract%3Frss%3Dyes Abstract: Aim: To assess systolic and diastolic function in adult childhood-cancer survivors (CCS) after treatment entailing potential cardiovascular toxicity.Methods: The study cohort consisted of 277 adult CCS (median age 28 [range 18–48]years), who had been treated with anthracyclines, platinum, and/or radiotherapy between 1976 and 1999, along with 130 healthy sibling controls. The assessments included echocardiography, baroreflex sensitivity measurement, and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP). Echocardiography measurements were shortening fraction (SF) (abnormal (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347010 Wed, 22 Jun 2011 04:00:00 +0100 5347010 http://www.medworm.com/index.php?rid=5273355&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003674%2Fabstract%3Frss%3Dyes Abstract: Background: Pancreatoblastoma is a very rare malignant tumour typically occurring in the early years of life. Due to its rarity, standardised diagnostic and therapeutic guidelines are not available for pancreatoblastoma.Methods: The newborn cooperative group denominated EXPeRT – European cooperative study group for paediatric rare tumours – combined in a joint analysis of all cases registered between 2000 and 2009 by the national groups of Italy, France, United Kingdom, Poland and Germany.Results: Twenty patients (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273355 Wed, 22 Jun 2011 04:00:00 +0100 5273355 http://www.medworm.com/index.php?rid=5638181&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003509%2Fabstract%3Frss%3Dyes Abstract: Background: In a double-blind, randomised phase III trial of advanced renal cell carcinoma patients, pazopanib 800mg QD (n=290) versus placebo (n=145) significantly prolonged progression-free survival (hazard ratio (HR)=0.46, 95% confidence interval [CI] 0.34–0.62, p-value (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5638181 Mon, 20 Jun 2011 04:00:00 +0100 5638181 http://www.medworm.com/index.php?rid=5400265&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003546%2Fabstract%3Frss%3Dyes Conclusions: Our results suggested that miR-429 played a role in the pathogenesis of gastric carcinoma and may function as a recessive cancer gene. c-myc is an important miR-429 target gene. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400265 Mon, 20 Jun 2011 04:00:00 +0100 5400265 http://www.medworm.com/index.php?rid=5347001&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003522%2Fabstract%3Frss%3Dyes Abstract: The number of cancer-related clinical trials has been rapidly increasing over the past decade. Along with this increase, oncology studies stopped early for benefit or harm have also been more common. Clinicians treating cancer patients often are faced with the challenge of having to decide whether or not to incorporate information from these new studies into their daily clinical practice. This review article explains the role of the Data and Safety Monitoring Committee in stopping trials early; provides examples of oncology trials stopped early; and reviews some of the controversies and statistical concepts associated with early stopping rules. In addition, a simple and practical approach to interpreting the findings of trials that are stopped early is provided to assist clinicia... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5347001 Mon, 20 Jun 2011 04:00:00 +0100 5347001 http://www.medworm.com/index.php?rid=5273352&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003534%2Fabstract%3Frss%3Dyes Conclusion: All regimens were active and PA met the criteria for further investigation, despite slightly higher haematological toxicity. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273352 Mon, 20 Jun 2011 04:00:00 +0100 5273352 http://www.medworm.com/index.php?rid=4998517&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100325X%2Fabstract%3Frss%3Dyes Conclusions: The percentage of patients with MBD treated with ZA at first chemotherapy (37.7%) is low. The addition of ZA increased OS in NSCLC patients with MBD in this audit. More formal policies and dedicated trials on the treatment of MBD in NSCLC patients need to be put in place. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=4998517 Sun, 19 Jun 2011 23:00:00 +0100 4998517 http://www.medworm.com/index.php?rid=5273349&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003777%2Fabstract%3Frss%3Dyes Abstract: Tumour recurrence and metastasis are pressing issues of hepatocellular carcinoma (HCC) patients who receive surgical treatments. Matrix metalloproteinase-12 (MMP-12), previously identified from our animal model, is involved in tumour invasiveness of rat hepatoma. We aimed to investigate the significance and prognostic value of MMP-12 expression in human HCC.MMP-12 mRNA level of 139 pairs of tumour and non-tumour liver tissues of HCC patients after hepatectomy were investigated by quantitative real-time RT-PCR.MMP-12 mRNA was significantly elevated in tumour liver tissues of HCC patients compared to non-tumour and normal liver tissues. By comparing paired tumour and non-tumour liver tissues, MMP-12 mRNA was overexpressed in 58% of tumour tissue of HCC patients. Overexpression of M... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273349 Fri, 17 Jun 2011 04:00:00 +0100 5273349 http://www.medworm.com/index.php?rid=5273356&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003236%2Fabstract%3Frss%3Dyes Abstract: Vascular endothelial growth factor C (VEGF-C) expression is associated with the malignant tumour phenotype making it an attractive therapeutic target. We investigated the biological roles of VEGF-C in tumour growth, migration, invasion and explored the possibility of VEGF-C as a potential therapeutic target for the treatment of non-small cell lung cancer (NSCLC). A lentivirus-mediated RNA interference (RNAi) technology was used to specifically knockdown the expression of VEGF-C in A549 cells. Quantitative reverse transcriptase-polymerase chain reaction, flow cytometry, Western blot, immunohistochemistry, cellular growth, migration, invasion and ELISA assays were used to characterise VEGF-C expression in vitro. A lung cancer xenograft model in nude mice was established to investig... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273356 Thu, 16 Jun 2011 04:00:00 +0100 5273356 http://www.medworm.com/index.php?rid=5494686&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003510%2Fabstract%3Frss%3Dyes Conclusion: Recent developments in the national cancer control agenda have included an increasing emphasis on outcome measures, with short-term cancer survival an operational measure of variation and progress in cancer control. In providing clues to the nature of the survival differences between socioeconomic groups, the results presented here give strong support for this strategy. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494686 Wed, 15 Jun 2011 04:00:00 +0100 5494686 http://www.medworm.com/index.php?rid=4923064&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003819%2Fabstract%3Frss%3Dyes (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=4923064 Mon, 13 Jun 2011 14:42:09 +0100 4923064 http://www.medworm.com/index.php?rid=5208029&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003170%2Fabstract%3Frss%3Dyes Conclusion: Hope, increased survival time and child quality of life are all more important factors to parents when decision-making at end-of-life compared to HCPs. Conversely, HCPs place greater emphasis on the families’ financial considerations than parents. Understanding these differences may aid in communication and improve end-of-life care for children with cancer. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208029 Mon, 13 Jun 2011 04:00:00 +0100 5208029 http://www.medworm.com/index.php?rid=5208021&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003248%2Fabstract%3Frss%3Dyes Abstract: Background: In Japan and South Korea, transarterial chemoembolisation (TACE) is an important locoregional treatment for patients with unresectable hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, has been shown effective and safe in patients with advanced HCC. This phase III trial assessed the efficacy and safety of sorafenib in Japanese and Korean patients with unresectable HCC who responded to TACE.Methods: Patients (n=458) with unresectable HCC, Child-Pugh class A cirrhosis and ⩾25% tumour necrosis/shrinkage 1–3months after 1 or 2 TACE sessions were randomised 1:1 to sorafenib 400mg bid or placebo and treated until progression/recurrence or unacceptable toxicity. Primary end-point was time to progression/recurrence (TTP). Secondary end-point was overall ... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208021 Mon, 13 Jun 2011 04:00:00 +0100 5208021 http://www.medworm.com/index.php?rid=5208020&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003467%2Fabstract%3Frss%3Dyes Abstract: Tumour staging in cancer patients generally entails a multimodality imaging approach. Whole-body (WB) imaging techniques may, however, be more time- and cost-effective than a multimodality approach. 2-Fluorine-18-fluoro-2-deoxy-d-glucose positron emission tomography (18FDG-PET), computed tomography (CT) and hybrid positron emission tomography and computed tomography (PET/CT) are the most established WB modalities, although new techniques, amongst which diffusion-weighted magnetic resonance imaging (DWI), are emerging. This review aims to evaluate the current evidence for WB-DWI in oncology, to discuss its potential for the WB staging of (colo)rectal cancer and to relate it to the established WB techniques. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208020 Mon, 13 Jun 2011 04:00:00 +0100 5208020 http://www.medworm.com/index.php?rid=5208018&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003224%2Fabstract%3Frss%3Dyes Conclusions: The combination of Myocet®, docetaxel and trastuzumab is safe and shows promising activity as first-line treatment of HER-2-positive MBC. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208018 Mon, 13 Jun 2011 04:00:00 +0100 5208018 http://www.medworm.com/index.php?rid=5109059&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003030%2Fabstract%3Frss%3Dyes Abstract: Background: Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5-fluorouracil or alone in patients previously treated with a fluoropyrimidine. We compared toxicity (particularly diarrhoea), quality of life, and efficacy of combination chemotherapy and irinotecan in these patients.Methods: In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180mg/m2 IV over 90min, day 1), 5-fluorouracil (400mg/m2 IV bolus and 2400mg/m2 by 46-hour infusion from day 1) and folinic acid (20mg/m2 IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350mg/m2 IV over 90min), 3-weekly. Tox... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5109059 Sun, 12 Jun 2011 23:00:00 +0100 5109059 http://www.medworm.com/index.php?rid=5494697&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003121%2Fabstract%3Frss%3Dyes Abstract: Human mesenchymal stem cells (hMSCs) have emerged as attractive cellular vehicles for gene therapy against brain malignancy because of their targeted tropism for cancer and the intrinsic attribute of autologous transplantation. We evaluated the characteristics and therapeutic potential of human adipose tissue-derived MSCs (hAT-MSCs) and prodrug gene therapy against diffuse pontine gliomas.The hAT-MSCs were isolated from human adipose tissue and characterised for morphology, surface markers and potential to differentiate into mesenchymal and neuronal lineages. We genetically modified hAT-MSCs to express rabbit carboxylesterase (rCE) enzyme, which can efficiently convert the prodrug CPT-11 (irinotecan-7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin), into the acti... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494697 Fri, 10 Jun 2011 04:00:00 +0100 5494697 http://www.medworm.com/index.php?rid=5494685&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003492%2Fabstract%3Frss%3Dyes In this study, pre-operative bevacizumab added to oxaliplatin, capecitabine and radiation was safe and resulted in a promising tumour regression rate. Surgical complications were closely monitored and occurred with the expected frequency. Central pathology review should be considered for trials with pathologic response as the primary end-point.Funding: British Columbia Cancer Agency, Hoffmann-La Roche Canada and Sanofi-Aventis. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5494685 Fri, 10 Jun 2011 04:00:00 +0100 5494685 http://www.medworm.com/index.php?rid=5208023&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003157%2Fabstract%3Frss%3Dyes This article reviews the classes of agents that have shown potential in this setting, notably chemotherapy drugs, hormonal therapies, immunotherapies, anti-angiogenic drugs, and clusterin-targeted therapy. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208023 Fri, 10 Jun 2011 04:00:00 +0100 5208023 http://www.medworm.com/index.php?rid=5208024&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003297%2Fabstract%3Frss%3Dyes Abstract: Purpose: To determine the objective response rate of malignant pleural mesothelioma (MPM) to short course radiation therapy.Methods: We reviewed the cases of 54 patients with advanced MPM who were treated with palliative radiotherapy according to a standardised institutional policy. Pre- and post-treatment computed tomography scans were used to assess response.Results: Fifty-seven percent of patients reported some improvement in their symptoms following radiotherapy. The radiology response rate was 43% (22 patients had a partial response and 1 patient a complete response). Response to treatment was correlated with the European Organisation for Research and Treatment of Cancer (EORTC) prognostic index (p=0.001), performance status (p=0.02) and histological subtype (p=0.04). In the... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208024 Thu, 09 Jun 2011 04:00:00 +0100 5208024 http://www.medworm.com/index.php?rid=5208019&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003273%2Fabstract%3Frss%3Dyes Abstract: Aim: To assess the role of ipsilateral breast radiotherapy (IBR) in women with occult primary breast cancer presenting with axillary metastases (OPBC).Methods: Patients with axillary nodal metastases and histological diagnosis of breast cancer without palpable, mammographic or ultrasonographic evidence of a breast primary were identified from a prospectively maintained single institution database. Imaging, surgery, radiotherapy, recurrence and survival data were collected. Patients whose breast cancer primary was detected on MRI (but occult on clinical examination and other imaging) were excluded from the analyses of IBR and outcome, but were included in other exploratory analyses.Results: Fifty-five patients were included between 1975 and 2009. Median follow up was 68months. Twe... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208019 Thu, 09 Jun 2011 04:00:00 +0100 5208019 http://www.medworm.com/index.php?rid=5143386&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003212%2Fabstract%3Frss%3Dyes Abstract: Although many studies show an increased risk of metachronous contralateral breast cancer (CBC) in women with a positive family history and young age at diagnosis of the initial breast cancer, the aetiological pathways are still enigmatic.In a cohort of 8478 primary breast cancer patients diagnosed between 1975 and 2006, 558 cases of metachronous CBC were identified. Using multivariate Cox proportional hazards models, we analysed risk factors assessed at the time of the first primary tumour, including patient demographics, tumour characteristics and treatment among 4681 breast cancer patients for whom data on key variables were available. The analysis was performed separately in patients who developed CBC without and with prior recurrence(s).Risk of CBC without prior recurrent dis... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5143386 Wed, 08 Jun 2011 23:00:00 +0100 5143386 http://www.medworm.com/index.php?rid=4998525&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003182%2Fabstract%3Frss%3Dyes Abstract: Purpose: Investigate circulating CCL5 in breast cancer patients and healthy controls, along with gene expression levels in corresponding tumour tissue and isolated primary stromal cells. Hormonal control of CCL5, and a potential relationship with TGFβ1, was also investigated.Methods: Circulating levels of CCL5 and TGFβ1 were measured in 102 breast cancer patients and 66 controls using ELISA. Gene expression levels (CCL5, CCR5, TGFβ1, TGFβRII) were quantified in corresponding tumour tissue (n=43), normal tissue (n=16), and isolated tumour (n=22) and normal (n=3) stromal cells using RQ-PCR. CCL5 and circulating menstrual hormones (LH, FSH, Oestradiol, Progesterone) were analysed in serum samples from healthy, premenopausal volunteers (n=60).Results: TGFβ1 was significantly hig... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=4998525 Wed, 08 Jun 2011 23:00:00 +0100 4998525 http://www.medworm.com/index.php?rid=5457089&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003480%2Fabstract%3Frss%3Dyes Abstract: The aim of this study was to evaluate the association of sensitivity to previous irinotecan-based chemotherapy with efficacy of cetuximab plus irinotecan therapy in metastatic colorectal cancer (MCRC) patients with wild-type KRAS. We analysed a pooled data set consisting of data from 87 MCRC patients from two previous phase II studies (n=60) and a group given off-protocol treatment (n=27) following irinotecan-, oxaliplatin-, and fluoropyrimidine-based chemotherapy. Overall objective response rate to cetuximab plus irinotecan was 28.7%, median progression-free survival (PFS) was 5.3months, and median overall survival was 12.2 months. Objective response rate did not significantly differ between patients with a favourable response to previous irinotecan (n=23), stable disease (n=38)... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5457089 Wed, 08 Jun 2011 04:00:00 +0100 5457089 http://www.medworm.com/index.php?rid=5273348&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003479%2Fabstract%3Frss%3Dyes Conclusions: In the treatment of resectable colorectal liver metastases, the addition of neo-adjuvant chemotherapy could be cost-effective because it makes it possible to avoid hepatic resection in patients who do not respond to the neo-adjuvant approach; however, the life-expectancy of the two strategies is very similar. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5273348 Wed, 08 Jun 2011 04:00:00 +0100 5273348 http://www.medworm.com/index.php?rid=5400273&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003285%2Fabstract%3Frss%3Dyes Conclusion: To the authors’ knowledge, this is the largest DNA repair-related SNP study in melanoma risk conducted in the Spanish population up to now. Furthermore, it also represents a comprehensive genetic study of several oxidative stress polymorphisms tested in relation to MM susceptibility. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400273 Mon, 06 Jun 2011 04:00:00 +0100 5400273 http://www.medworm.com/index.php?rid=5109051&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003261%2Fabstract%3Frss%3Dyes Few subjects have generated as much regulatory discussion as the choice of primary endpoints in phase III trials in the advanced or metastatic cancer setting. Acknowledging that overall survival (OS) remains the most objective and clinically convincing endpoint to support a favourable decision on the benefit-risk balance and to change clinical practice, progression-free survival (PFS) has also been proposed as the primary endpoint to support drug approval. Although the interplay between PFS and OS remains unknown for most agents, and particularly for new ones, a primary rationale for using PFS is that this endpoint could be considered as a clinical benefit endpoint in itself, provided the treatment effect is sufficiently large. From the perspective of drug developers, the interest in PFS i... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5109051 Sun, 05 Jun 2011 23:00:00 +0100 5109051 http://www.medworm.com/index.php?rid=5208027&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003169%2Fabstract%3Frss%3Dyes Conclusions: The reduced miR-100 expression participates in the development of cervical cancer at least partly through loss of inhibition to target gene PLK1, which probably occurs in a relative late phase of carcinogenesis. HR-HPV E6/E7 may not directly regulate miR-100 expression in cervical cells. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208027 Thu, 02 Jun 2011 04:00:00 +0100 5208027 http://www.medworm.com/index.php?rid=5208026&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003145%2Fabstract%3Frss%3Dyes Conclusion: In general, TLH should be recommended as the standard surgical procedure in early stage endometrial cancer, also in patients >70years of age. In obese patients with a BMI >35kg/m2 TLH is not cost effective because of the high conversion rate. A careful consideration of laparoscopic treatment is needed for this subgroup. Surgeon experience level may influence this choice. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208026 Thu, 02 Jun 2011 04:00:00 +0100 5208026 http://www.medworm.com/index.php?rid=5208035&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003078%2Fabstract%3Frss%3Dyes In conclusion, the TF-VIIa complex plays an important role in invasion-metastasis by enhancing tumour cell infiltration ability and forming microthrombi. The newly established anti-human TF neutralisation antibody may be useful for the treatment of pancreatic and other invasive cancers. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208035 Mon, 30 May 2011 04:00:00 +0100 5208035 http://www.medworm.com/index.php?rid=5208030&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003133%2Fabstract%3Frss%3Dyes Abstract: ‘Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship (PROFILES)’ is a registry for the study of the physical and psychosocial impact of cancer and its treatment from a dynamic, growing population-based cohort of both short and long-term cancer survivors. PROFILES contains a large web-based component and are linked directly to clinical data from the population-based Eindhoven cancer registry. This paper describes the rationale and design of PROFILES.The primary aims of studies that use the PROFILES registry are: (1) psychosocial risk and outcome assessment to identify patients at high risk for poor physical and mental health outcomes, (2) to analyse mediating mechanisms to better understand the biological and behavioural factors assoc... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208030 Mon, 30 May 2011 04:00:00 +0100 5208030 http://www.medworm.com/index.php?rid=5109060&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003042%2Fabstract%3Frss%3Dyes Abstract: Aim of the study: Loss of the nuclear lamina protein lamin A/C (LMNA) has been observed in several human malignancies. The present study aimed to investigate associations between LMNA expression and clinical outcome in colon cancer patients.Patients and methods: Clinicopathological data and formalin-fixed paraffin embedded tissues were collected from 370 stage II and III colon cancer patients. Tissue microarrays were constructed, stained for lamin A/C and evaluated microscopically. Microsatellite instability status was determined for 318 tumours.Results: Low levels of LMNA expression were observed in 17.8% of colon tumours, with disease recurrence occurring in 45.5% of stage II and III colon cancer patients with LMNA-low expressing tumours compared to 29.6% of patients with LMNA-... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5109060 Sun, 29 May 2011 23:00:00 +0100 5109060 http://www.medworm.com/index.php?rid=5400272&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911002887%2Fabstract%3Frss%3Dyes This study confirmed no increased risk of CM with the use of oral contraceptives and hormone replacement therapy: exogenous female hormones do not contribute to an increased risk of CM. In contrast, significant associations of CM with parity and age at first pregnancy were observed in this meta-analysis finds and warrant further research. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5400272 Fri, 27 May 2011 04:00:00 +0100 5400272 http://www.medworm.com/index.php?rid=5143391&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911002838%2Fabstract%3Frss%3Dyes Conclusions: The findings of this study suggest that the CYP1A1*2A polymorphism is a predictor for clinical outcome in NSCLC patients treated with EGFR-TKI therapy, and combining analysis of both CYP1A1*2A and EGFR intron 1 (CA)n polymorphisms may be useful for predicting treatment outcome in NSCLC patients treated with EGFR-TKIs. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5143391 Thu, 26 May 2011 23:00:00 +0100 5143391 http://www.medworm.com/index.php?rid=4863775&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003339%2Fabstract%3Frss%3Dyes (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=4863775 Thu, 26 May 2011 14:35:18 +0100 4863775 http://www.medworm.com/index.php?rid=5208036&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100311X%2Fabstract%3Frss%3Dyes Abstract: Mitomycin C (MMC) potently suppresses tumour growth. However, its use is limited by its severe toxicity to the kidney and bone marrow. The purpose of this study is to investigate whether the chemoprevention agent curcumin can reduce MMC-associated side-effects and improve MMC efficacy in a breast cancer xenograft model. We first determined the effectiveness of combined MMC and curcumin to inhibit in vitro cell growth and to regress in vivo tumour outgrowth. We then investigated the mechanisms associated with MMC/curcumin-induced cell death by examining the effect of MMC/curcumin treatment on apoptosis, the activation of caspase-3, 8 and 9 and the expression of bcl-2 and bax. We also evaluated the ability of curcumin to alleviate MMC-associated side-effects by comparing the levels... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208036 Thu, 26 May 2011 04:00:00 +0100 5208036 http://www.medworm.com/index.php?rid=5208031&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911002875%2Fabstract%3Frss%3Dyes Abstract: Aim: To explore whether the self-reported psychological distress among men with prostate cancer was to the extent that it required psychiatric treatment.Methods: PCBaSe Sweden, a merged database based on the National Prostate Cancer Register including 97% of all prostate cancers registered as well as age-matched controls. We calculated relative risks and 95% confidence intervals to compare risks of psychiatric treatment due to depression, anxiety, and post-traumatic stress disorder controlling for age and socio-economic factors. We used odds ratios to compare use or no use of antidepressants.Findings: In total 72,613 men with prostate cancer and 217,839 men without prostate cancer were included for analyses. Psychiatric hospitalisation due to depression, anxiety and post-traumati... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208031 Thu, 26 May 2011 04:00:00 +0100 5208031 http://www.medworm.com/index.php?rid=5143396&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003108%2Fabstract%3Frss%3Dyes Conclusion: Cancer patients on a surgical ward benefit from psycho-oncological support especially at an early stage of therapy but also over a long time after discharge from the hospital. The aim of all interventions should be to decrease psychological distress and disorders and thereby improve the quality of life for cancer patients. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5143396 Wed, 25 May 2011 23:00:00 +0100 5143396 http://www.medworm.com/index.php?rid=5143393&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS095980491100308X%2Fabstract%3Frss%3Dyes Conclusions: Management of melanoma in Germany did not show great dependency on centre size, geographical area or treating physician but rather on patient and tumour characteristics. The low rate of adjuvant treatment initiations reflects the need of treatment options in this patient group. Excessive initial staging procedures generate significant costs. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5143393 Wed, 25 May 2011 23:00:00 +0100 5143393 http://www.medworm.com/index.php?rid=5109055&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003066%2Fabstract%3Frss%3Dyes Abstract: Hepatocellular carcinoma has an increasing incidence and high mortality. Treatment options are limited if the disease is not diagnosed in its early stage. The natural course of the disease is aggressive but not always predictable. Molecular profiling is a promising tool for classification in order to optimize prognosis prediction and treatment for an individual patient. In the last decade a large amount of studies has been conducted to better classify hepatocellular carcinomas. The focus of this review is on implications of molecular classification for prognosis and therapeutic decision making in HCC patients. Most studies used microarray technique for genome wide profiling, but other methods to detect genomic changes and microRNA are gaining interest. The whole genome profiling ... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5109055 Wed, 25 May 2011 23:00:00 +0100 5109055 http://www.medworm.com/index.php?rid=5208034&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911003054%2Fabstract%3Frss%3Dyes Conclusion: Our results show that the FAS1–2 domain of PN plays a role in tumour progression. Moreover this novel antibody may likewise prove to be very useful in clarifying the role of PN in angiogenesis and may contribute to the design of novel anti-angiogenesis drugs. (Source: European Journal of Cancer) European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5208034 Wed, 25 May 2011 04:00:00 +0100 5208034 http://www.medworm.com/index.php?rid=5143403&cid=s_35537_6_f&fid=35537&url=http%3A%2F%2Fwww.ejcancer.info%2Farticle%2FPIIS0959804911002863%2Fabstract%3Frss%3Dyes Abstract: Inappropriate gene silencing and subsequent promiscuous activity define the transformation of many solid tumours including renal cell carcinoma (RCC). Here, we report that UNC5C, one of the Netrin-1 receptors, was frequently inactivated in RCC cell lines and primary tumours. UNC5C protein was expressed in the proximal convoluted tubules of the human kidney, the presumed origin of clear cell RCC (ccRCC) and papillary RCC (pRCC). Compared to paired adjacent non-malignant tissues, both UNC5C mRNA and protein expression were significantly down-regulated in RCC. Immunohistochemical analysis showed that UNC5C was inactivated in 94.3% of the samples and the loss of UNC5C occurred at the early stage of RCC. Methylation specific PCR showed that UNC5C promoter was methylated in two renal c... European Journal of Cancer journals http://www.medworm.com/rss/comments.php?id=5143403 Tue, 24 May 2011 23:00:00 +0100 5143403